Viemed Healthcare Inc Stock Price, News & Analysis

Viemed Healthcare announced a share repurchase program authorizing the buyback of up to 1,976,441 common shares (5% of outstanding shares) through June 2026. The company plans to make purchases through open market and block trades, with daily purchases limited to 25% of the previous 4-week average daily volume. CEO Casey Hoyt highlighted strong Q1 2025 results and increased 2025 guidance, noting the company's disciplined capital allocation strategy. Viemed has previously repurchased 2.6 million shares since going public. With no net debt and full access to a $55 million credit facility, the company maintains sufficient liquidity for both the buyback program and growth initiatives, including the pending Lehan's Medical acquisition expected to close in Q3 2025.

Viemed Healthcare (NASDAQ:VMD), a leading provider of respiratory care and technology-enabled home medical equipment services, has announced its participation in the 15th Annual East Coast IDEAS Investor Conference. The company's presentation is scheduled for June 11, 2025, at 11:30am ET at The Westin Times Square in New York, NY. Investors and interested parties can access the presentation through the conference website at www.threepartadvisors.com/east-coast or via Viemed's investor relations section at viemed.com/investors.

Viemed Healthcare (NASDAQ:VMD) reported strong Q1 2025 financial results with net revenues of $59.1M, up 17% year-over-year. Net income reached $2.6M ($0.06 per diluted share), a 64% increase from Q1 2024. The company's Adjusted EBITDA grew 26% to $12.8M. Patient metrics showed solid growth with ventilator patients up 13% YoY to 11,809, and PAP therapy patients increasing 46% YoY to 22,899. Viemed maintains a strong financial position with $10.2M in cash and $55M available in credit facilities. The company raised its 2025 guidance, now expecting revenues of $256-265M and Adjusted EBITDA of $55-58M. Additionally, Viemed announced plans to acquire Lehan's Medical Equipment for $26M in Q3 2025, which generated $25.7M in revenue and $7.4M in Adjusted EBITDA in 2024.

Viemed Healthcare (NASDAQ: VMD) has announced a $26 million acquisition of Illinois-based Lehan's Medical Equipment, a healthcare provider specializing in home medical equipment, respiratory care, and women's health. Founded in 1946, Lehan operates three full-service locations in Northern Illinois and three sleep/CPAP setup locations in West Chicagoland and Wisconsin. The acquisition brings significant financial value, as Lehan generated $25.7 million in net revenues and $7.4 million in Adjusted EBITDA in 2024. The deal, expected to close in Q3 2025, includes a base purchase price of $26 million plus an estimated $2.2 million in contingent payments. Viemed will retain Lehan's 90+ employees and current owners, funding the acquisition through cash on hand and existing credit facilities.

Viemed Healthcare (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming First Quarter 2025 Earnings Conference Call. The call is scheduled for Thursday, May 8, 2025, at 11:00 a.m. EDT.

Participants can join via phone using US Toll-Free (866) 682-6100 or International +1 (862) 298-0702. A live audio webcast will be available, and a replay will be accessible in the Investor Relations section of Viemed's website after the call.

Viemed Healthcare (NASDAQ:VMD) reported record financial results for Q4 and full-year 2024. The company achieved Q4 net revenues of $60.7 million, up 20% year-over-year, while full-year revenues reached $224.3 million, increasing 23% from 2023.

Q4 net income was $4.3 million ($0.10 per diluted share), up 24% YoY, with full-year net income at $11.3 million ($0.28 per diluted share), marking the eighth consecutive year of profitability. The company expanded its patient base significantly, with ventilator patients up 14% to 11,795, PAP therapy patients up 43% to 21,338, and sleep resupply patients up 29% to 24,478.

For 2025, Viemed projects net revenue between $254-265 million and adjusted EBITDA of $54-58 million. The company maintains a strong financial position with $17.5 million in cash and $55 million available in credit facilities.

Viemed Healthcare (NASDAQ: VMD), a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming Year End 2024 earnings conference call. The call is scheduled for Tuesday, March 11, 2025, at 11:00 a.m. EDT.

Interested participants can join the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International). A live audio webcast will also be available through a dedicated link.

Following the live call, a replay will be accessible in the Investor Relations section of Viemed's website at www.viemed.com. This announcement allows investors and analysts to prepare for the company's presentation of its financial results and performance for the full year 2024.

Viemed Healthcare reported strong Q3 2024 financial results with net revenues increasing 17.4% to $58.0 million, setting a company record. Net income rose 33% to $3.9 million ($0.10 per diluted share), while Adjusted EBITDA grew 15.5% to $14.0 million. The company expanded its ventilator patient count by 11.0% to 11,374 and increased sleep therapy patients by 11.0% to 19,478. With a strong cash balance of $11.3 million and $55.3 million available in credit facilities, Viemed projects Q4 2024 revenues between $59.7-60.9 million, exceeding previous guidance.

Viemed Healthcare, a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming third quarter 2024 earnings conference call. The call is scheduled for Thursday, November 7, 2024, at 12:00 p.m. EST.

Interested parties can participate in the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International). A live audio webcast will also be available. Following the live call, a replay will be accessible in the Investor Relations section of Viemed's website at www.viemed.com.